Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Apotex	CETIRIZINE HYDROCHLORIDE ALLERGY	cetirizine hydrochloride	CAPSULE;ORAL	207235	ANDA	Topco Associates LLC	36800-180-09	1 BOTTLE in 1 PACKAGE (36800-180-09) / 65 CAPSULE, LIQUID FILLED in 1 BOTTLE	2020-06-06
Apotex	CETIRIZINE HYDROCHLORIDE ALLERGY	cetirizine hydrochloride	CAPSULE;ORAL	207235	ANDA	Topco Associates LLC	36800-180-63	1 BOTTLE in 1 PACKAGE (36800-180-63) / 25 CAPSULE, LIQUID FILLED in 1 BOTTLE	2020-06-06
Apotex	CETIRIZINE HYDROCHLORIDE ALLERGY	cetirizine hydrochloride	CAPSULE;ORAL	207235	ANDA	Meijer Distribution Inc	41250-618-63	1 BOTTLE in 1 PACKAGE (41250-618-63) / 25 CAPSULE, LIQUID FILLED in 1 BOTTLE	2020-06-02
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

A comprehensive review of suppliers for cetirizine hydrochloride, the active pharmaceutical ingredient (API) in widely used allergy medications, indicates a consolidated market dominated by manufacturers in Asia, particularly China and India. Key players offer various grades of the API, with pricing influenced by volume, purity standards, and regulatory compliance. Pharmaceutical companies rely on a combination of direct sourcing and distributors to secure supply, facing potential risks associated with geopolitical factors and supply chain disruptions.

Who are the primary manufacturers of Cetirizine Hydrochloride API?

The global manufacturing landscape for cetirizine hydrochloride API is concentrated among a limited number of companies, primarily located in Asia. These manufacturers operate under strict quality control measures to meet international pharmacopeial standards.

China: Holds a significant share of global production. Companies like Zhejiang Huahai Pharmaceutical Co., Ltd. and Hubei Biocause Pharmaceutical Co., Ltd. are recognized as major producers. These entities often benefit from economies of scale and integrated production processes.
India: Also a substantial contributor to the global supply. Key players include Dr. Reddy's Laboratories and Sun Pharmaceutical Industries Ltd., which have established reputations for API manufacturing and export.
European Union: While production exists, it is less dominant compared to Asian manufacturing. Some specialized or niche manufacturers may operate within the EU, often focusing on higher-purity grades or serving regional markets.

The production capacity and output volume of these manufacturers are critical determinants of global availability and pricing. Fluctuations in raw material costs, environmental regulations, and manufacturing plant expansions or closures directly impact the supply chain.

What are the different grades and specifications of Cetirizine Hydrochloride API available?

Cetirizine hydrochloride API is available in various grades, distinguished by purity levels, particle size, crystalline form, and compliance with specific pharmacopeias. These specifications are crucial for formulators to ensure the final drug product's efficacy, stability, and safety.

Pharmacopeial Grades: The most common grades adhere to standards set by major pharmacopeias:
- USP (United States Pharmacopeia): Defines purity, assay, and impurity limits for API intended for the U.S. market.
- EP (European Pharmacopoeia): Similar to USP, but with specifications aligned with European regulatory requirements.
- BP (British Pharmacopoeia): Historically significant, now largely harmonized with EP.
- JP (Japanese Pharmacopoeia): Standards for the Japanese pharmaceutical market. Manufacturers typically offer API that meets one or more of these pharmacopeial monographs.
Purity Levels:
- Standard Grade: Generally meets the minimum purity requirements of the target pharmacopeia (e.g., ≥ 98.5%).
- High-Purity Grade: Offers enhanced purity (e.g., ≥ 99.0% or higher), with significantly lower levels of specific impurities. This is often preferred for formulations requiring extended shelf life or stringent regulatory approval.
Particle Size Distribution: The micronization of cetirizine hydrochloride API influences its dissolution rate and bioavailability. Manufacturers can provide API with controlled particle size ranges (e.g., d10, d50, d90 values) to optimize formulation characteristics.
Crystalline Form (Polymorphism): Cetirizine hydrochloride can exist in different crystalline forms, which can affect its physical properties like solubility, stability, and manufacturing processability. Suppliers may offer specific polymorphs upon request, or they may control their manufacturing process to ensure consistency in the crystalline form.

Manufacturers provide Certificates of Analysis (CoA) with each batch, detailing the results of quality control tests against the specified grade and pharmacopeial standards.

What are the key regulatory considerations for Cetirizine Hydrochloride API suppliers?

Suppliers of cetirizine hydrochloride API must comply with a complex web of international and national regulations to ensure product quality, safety, and traceability. Non-compliance can lead to import alerts, product recalls, and significant financial penalties.

Good Manufacturing Practices (GMP): Adherence to cGMP is mandatory. This includes robust quality management systems, validated manufacturing processes, strict environmental controls, and comprehensive documentation. Manufacturers are regularly inspected by regulatory authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically file DMFs (in the U.S.) or ASMFs (in Europe) with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, quality control, and stability of the API. Pharmaceutical companies reference these filings in their drug product marketing applications.
Impurity Profiling and Control: Regulatory bodies place increasing emphasis on controlling impurities, including genotoxic impurities and residual solvents, to levels that pose no risk to patient safety. Suppliers must demonstrate rigorous analytical testing and control strategies. The identification and qualification of process-related impurities and degradants are critical.
Supply Chain Integrity and Traceability: Regulations require robust systems for tracking API from its origin through manufacturing and distribution. This includes measures against counterfeiting and ensuring secure handling and storage.
Environmental, Social, and Governance (ESG) Factors: While not always directly mandated by pharmaceutical regulators, growing investor and societal pressure drives demand for suppliers with strong ESG practices, including responsible waste management, labor practices, and ethical sourcing.

Suppliers that maintain consistent compliance and transparent reporting are preferred partners for pharmaceutical firms navigating global markets.

What is the typical pricing structure and influencing factors for Cetirizine Hydrochloride API?

The pricing of cetirizine hydrochloride API is subject to multiple variables, reflecting production costs, market dynamics, and supplier-specific capabilities. A typical price range can fluctuate significantly based on these factors.

Volume Discounts: Larger purchase orders generally command lower per-kilogram pricing. Bulk purchases (e.g., multi-ton orders) offer the most favorable rates compared to spot buys or smaller quantities.
Purity and Grade: Higher purity grades, stricter impurity limits, and compliance with multiple pharmacopeias (e.g., USP/EP/JP dual-compendial) will typically result in higher pricing due to the increased complexity and cost of manufacturing and testing.
Manufacturing Location and Costs: Producers in regions with lower labor and overhead costs (e.g., China, India) often offer more competitive pricing. However, factors like shipping costs, import duties, and currency exchange rates can offset these advantages.
Regulatory Compliance and Certifications: Suppliers with advanced GMP certifications, a strong history of regulatory inspections, and well-maintained DMFs/ASMFs may command a premium. The cost associated with maintaining these standards is factored into their pricing.
Raw Material Volatility: The cost of key starting materials used in the synthesis of cetirizine hydrochloride can impact API pricing. Fluctuations in the petrochemical or chemical intermediate markets can lead to price adjustments.
Market Demand and Competition: Periods of high demand for allergy medications, coupled with limited supplier capacity, can drive prices up. Conversely, oversupply or intense competition among manufacturers can lead to price erosion.
Payment Terms and Contract Duration: Negotiated payment terms and the length of supply contracts can also influence the effective per-unit cost. Longer-term agreements often provide price stability.

A general estimated price range for bulk cetirizine hydrochloride API can fall between $30 to $70 per kilogram, but this is highly variable. Small research quantities or highly specialized grades can cost significantly more on a per-gram basis. Pharmaceutical companies often engage in competitive bidding and long-term supply agreements to secure stable pricing and supply.

How do pharmaceutical companies secure their Cetirizine Hydrochloride API supply?

Pharmaceutical companies employ diverse strategies to ensure a reliable and compliant supply of cetirizine hydrochloride API, mitigating risks associated with single-source dependency and market volatility.

Dual Sourcing / Multi-Sourcing: The most common strategy involves qualifying and maintaining relationships with at least two, and often three, independent API suppliers. This mitigates the risk of supply disruption due to quality issues, regulatory actions, or geopolitical events affecting a single manufacturer.
Direct Sourcing vs. Distributor Partnerships:
- Direct Sourcing: Larger pharmaceutical companies often establish direct relationships with API manufacturers. This allows for greater control over quality, direct communication on specifications, and potentially better pricing through volume negotiations. It requires significant internal resources for supplier qualification, auditing, and management.
- Distributor Partnerships: Smaller companies or those seeking to simplify their supply chain often work with specialized pharmaceutical distributors. These distributors aggregate supply from multiple manufacturers, manage inventory, handle logistics, and often provide regulatory support. While potentially more expensive per unit, distributors offer convenience and reduced administrative burden.
Strategic Stockpiling: Companies may maintain strategic reserves of API to buffer against unexpected supply interruptions. The size of this buffer is determined by lead times, market stability, and product demand.
Geographic Diversification: Sourcing API from manufacturers in different geographical regions (e.g., both China and India) can reduce the impact of regional disruptions such as natural disasters, trade disputes, or localized regulatory crackdowns.
Supplier Audits and Quality Agreements: Rigorous onsite audits of manufacturing facilities are standard practice. Comprehensive Quality Agreements are established between the pharmaceutical company and the API supplier, outlining specific responsibilities regarding quality, change control, complaint handling, and regulatory compliance.
Long-Term Supply Contracts: Entering into multi-year supply contracts provides price stability and a commitment from the supplier for a certain volume, enhancing supply chain predictability.
Continuous Market Monitoring: Pharmaceutical procurement and supply chain teams actively monitor global API markets, including news from regulatory agencies, geopolitical developments, and competitor activities, to anticipate potential supply issues.

The selection of a supplier involves a detailed evaluation of manufacturing capabilities, quality systems, regulatory track record, financial stability, and customer service.

What are the potential risks and challenges in the Cetirizine Hydrochloride supply chain?

The supply chain for cetirizine hydrochloride, like many APIs, is subject to several inherent risks and ongoing challenges that can impact availability, quality, and cost.

Geopolitical Instability and Trade Policies: Trade disputes, tariffs, and international sanctions can disrupt the flow of goods and raw materials. For instance, reliance on a single country for a significant portion of API production creates vulnerability to that country's political and economic climate.
Regulatory Scrutiny and Compliance Changes: Evolving regulatory expectations, particularly concerning impurity control and data integrity, can necessitate significant investment by API manufacturers to remain compliant. Non-compliance can lead to import bans or product recalls, creating immediate supply shortages.
Quality Control Failures and Recalls: Manufacturing errors, contamination, or deviations from GMP can result in batch failures and product recalls. Such events can lead to immediate stock depletion and damage supplier reputation, potentially triggering the need to find alternative suppliers.
Environmental Regulations and Enforcement: Stricter environmental regulations, particularly in major manufacturing hubs like China, can lead to temporary or permanent plant closures for non-compliant facilities. This can significantly reduce global supply capacity.
Raw Material Shortages and Price Volatility: Dependence on specific chemical intermediates or raw materials can expose the supply chain to shortages or price spikes if those upstream materials are affected by production issues or market demand.
Logistical Challenges: Shipping delays, increased freight costs, and port congestion, exacerbated by global events, can impact the timely delivery of API to formulation sites.
Intellectual Property and Counterfeiting: While cetirizine hydrochloride is largely off-patent, risks associated with intellectual property, unauthorized manufacturing, and the potential for counterfeit API entering the supply chain remain a concern.
Consolidation of Manufacturing Base: The trend towards consolidation among API manufacturers can, in some cases, reduce the number of viable suppliers, increasing reliance on a smaller group and potentially weakening negotiating power for buyers.

Proactive risk management, including dual sourcing, robust supplier qualification, and contingency planning, is essential for pharmaceutical companies to navigate these challenges.

Key Takeaways

The global supply of cetirizine hydrochloride API is dominated by manufacturers in China and India, with European production being less significant.
API is available in various pharmacopeial grades (USP, EP, etc.), with purity, particle size, and polymorphic form being key differentiators influencing price and application.
Suppliers must adhere to strict GMP regulations, maintain DMFs/ASMFs, and demonstrate rigorous impurity control to meet global pharmaceutical standards.
Pricing is driven by volume, grade, manufacturing location, regulatory compliance, raw material costs, and market demand, with bulk API generally ranging from $30-$70/kg.
Pharmaceutical companies typically employ dual-sourcing, direct sourcing or distributor partnerships, and stockpiling to secure a reliable supply.
Key risks in the supply chain include geopolitical instability, evolving regulatory landscapes, quality control failures, environmental enforcement, and logistical disruptions.

FAQs

What is the typical lead time for ordering Cetirizine Hydrochloride API in bulk? Lead times for bulk orders of cetirizine hydrochloride API can range from 8 to 16 weeks, depending on the manufacturer's current production schedule, order volume, and shipping logistics. Rush orders may be possible but often incur additional costs.
How can I verify the GMP compliance of a Cetirizine Hydrochloride API supplier? Verification of GMP compliance involves reviewing the supplier's latest inspection reports from regulatory authorities (e.g., FDA EIR, EMA inspection reports), requesting copies of their current GMP certificate, and conducting an on-site audit of their manufacturing facilities. A robust Quality Agreement is also essential.
What are the primary impurities to monitor in Cetirizine Hydrochloride API? Key impurities to monitor include process-related impurities such as starting materials and intermediates, degradation products formed during storage or manufacturing, and residual solvents used in the synthesis. Specific impurities are detailed in pharmacopeial monographs (e.g., USP, EP).
Can a single API manufacturer supply enough Cetirizine Hydrochloride for a global pharmaceutical market? While a few large manufacturers possess significant production capacity, the global market is typically served by a combination of multiple major producers to meet the overall demand and ensure supply chain resilience. No single entity accounts for the entirety of global production.
What is the shelf life of Cetirizine Hydrochloride API, and how is it determined? The shelf life of cetirizine hydrochloride API is typically determined by stability studies conducted by the manufacturer according to ICH guidelines. Common shelf lives are often in the range of 2 to 5 years when stored under specified conditions, but this can vary based on the specific grade and packaging.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-files/drug-master-files [2] European Medicines Agency. (n.d.). Active substance master file procedure. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-expert-groups/quality-biologics-novel-therapies/active-substance-master-file-procedure [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/page/guidelines [4] United States Pharmacopeia. (n.d.). General Chapters. In United States Pharmacopeia-National Formulary. [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia-ph

Suppliers and packagers for CETIRIZINE HYDROCHLORIDE ALLERGY

CETIRIZINE HYDROCHLORIDE ALLERGY

Cetirizine Hydrochloride Allergy Drug Supply Chain Analysis